Appalachian Node

摘要： NIDA临床试验网络（CTN）的阿巴拉契亚节点将解决出现的临床研究问题 来自阿巴拉契亚中部，目前阿片类药物流行的中心。它是阿片类药物使用率最高的国家之一 吸毒过量死亡和相关疾病它的乡村地理，独立文化，紧张 经济不景气和缺乏获得药物使用治疗的机会都是造成这一流行病的原因。连接在一起 匹兹堡大学（皮特），西弗吉尼亚大学（WVU）和宾夕法尼亚州立大学医学院（PSU）， 阿巴拉契亚节点将由经验丰富的临床研究人员，博士简Liebschutz（皮特）和朱迪思 Feinberg（WVU）.该节点将汇集成功的多学科合作研究者，其中许多人 在其他已建立节点的CTN经验，并已被招募到这些机构响应 区域性药物滥用的流行。附属学术医疗中心覆盖中西部 Pennsylvania（PA）和West Virginia（WV）的所有数据库，并拥有广泛的生物信息学数据库， 健康记录和索赔数据。利用利益相关者咨询小组，区域付款人的支持， 与州和地方政策以及公共卫生官员的联系将确保研究具有相关性和高效率。 研究完成后的可持续性。该节点的三个目标是：1）进行多地点试验 这将解决目前的阿片类药物危机（和其他药物滥用），重点是进行研究 在农村和其他得不到充分服务的人口中，2）提出研究，以测试现有资源的创新用途 （当地药店、同伴导航员/同伴康复教练、移动的技术、最先进的健康信息 系统）实施循证实践，将最先进的护理扩展到资源贫乏的地区， 农村和城市，以及3）传播CTN的调查结果，以区域付款人和决策者，从业人员， 社会各界该节点将确定当地解决方案，以克服服务不足地区障碍的复杂相互作用。 农村和城市地区。结合我们的资源和CTN提供的资源，我们将能够 对阿巴拉契亚中部和全国的阿片类药物流行产生重大影响。拟议的研究建立在工作 节点研究者包括：1）与注射药物用途：质量保证相关的严重细菌感染， 干预（Liebschutz，Pollini），2）药剂师辅助丁丙诺啡治疗（Winstanley），3）利用 学习健康系统，以激励药物辅助恢复阿片类药物使用障碍（克雷默）， 和4）智能手机应用程序和可穿戴设备的复发风险“预警”系统（川崎， Winstanley）。

Abstract: The Appalachian Node of NIDA Clinical Trials Network (CTN) will address clinical research questions that arise from Central Appalachia, an epicenter of the current opioid epidemic. It has among the highest rates of opioid overdose deaths and related morbidities in the nation. Its rural geography, culture of independence, strained economy and lack of access to substance use treatment have all contributed to the epidemic. Joining together University of Pittsburgh (Pitt), West Virginia University (WVU) and Penn State College of Medicine (PSU), the Appalachian Node will be led by experienced clinical investigators, Drs. Jane Liebschutz (Pitt) and Judith Feinberg (WVU). The node will bring together successful multi-disciplinary co-investigators, many of whom had prior CTN experience in other established nodes and who have been recruited to these institutions to respond to the regional substance use epidemic. The affiliated academic medical centers cover central and western Pennsylvania (PA) and all of West Virginia (WV) and have extensive bioinformatics databases with electronic health record and claims data. Use of a Stakeholder Advisory Group, support from regional payors, and close ties with state and local policy and public health officials will ensure that research has relevance and a high likelihood of sustainability after study completion. The three aims of the node are to: 1) conduct multisite trials that will address the current opioid crisis (and other substance misuse), with an emphasis on conducting studies among rural and other underserved populations, 2) propose studies to test innovative uses of existing resources (local pharmacies, peer navigators/peer recovery coaches, mobile technology, state-of-the-art health information systems) to implement evidence-based practices that will extend state-of-the-art care into resource-poor regions, both rural and urban, and 3) disseminate CTN findings to regional payers and policymakers, practitioners, and the community. The node will define local solutions to overcome the complex interplay of barriers in underserved rural and urban areas. The combination of our resources and those provided by the CTN will enable us to make a significant impact on the opioid epidemic in central Appalachia and nationally. Proposed studies built on work of node investigators include: 1) Serious Bacterial Infections Related to Injection Drug Use: Quality Metrics and Intervention (Liebschutz, Pollini), 2) Pharmacist-Assisted Buprenorphine Treatment (Winstanley), 3) Leveraging the Learning Health System to Incentivize Medication-Assisted Recovery for Opioid Use Disorder (Kraemer), and 4) An “Early Warning” System for Relapse Risk with Smartphone Apps and Wearable Devices (Kawasaki, Winstanley).